Research

Despite the rate of incidence and the high levels of recurrence and mortality, bladder cancer has long been overlooked in terms of research spending. Unlike for many other cancers, there have been few advances in new treatments or improvements in survival rates over the past thirty years. Other, less common cancers, have received support and resources and consequently have demonstrated a significant improvement in outcomes for patients.  We want the same for bladder cancer patients.

Encouraging and supporting research into bladder cancer is one of our core aims as a charity.

ABC UK Grants

As well as participating in and supporting research, we also actively encourage and fund research.

Our annual small grants programmes will soon be open for applications.

Further information, guidelines and application forms for the ABC UK Improving Patient Outcomes Programme and ABC UK Nurses Grants Programme, can be found on the ABC UK Grants page.

Both programmes support high-quality, stand-alone projects that deliver clear outcomes, whether data-led, clinical, or laboratory based. Projects may explore new approaches, share best practice, or serve as catalysts for further research, but must always focus on improving outcomes and experiences for people with bladder cancer.

Find out more

Action Bladder Cancer UK is a National Institute for Health Research (NIHR) non-commercial partner. This means the studies that we fund may be eligible to access NIHR Clinical Research Network support.  You can find more details on the ABC UK Grants page
 

NIHR-removebg-preview.png 

Clinical Trials

There are various clinical trials into bladder cancer in the UK. You can find out more about trials and how to find a trial here - Clinical Trials 

We need to raise funding to support bladder cancer research - see how you can help.  

How we help you

Latest News / Events

New treatment for advanced bladder cancer approved by NICE 21/08/2025

Action Bladder Cancer UK are pleased that NICE have approved a new treatment for use within the NHS in England and Wales.  Enfortumab vedotin with pembrolizumab (EVP) will be available for use in treating patients with untreated unresectable (cancer which cannot be completely ...

News & Events
Read more

We're on Twitter

Facebook